Quest Diagnostics Incorporated (DGX)
NYSE · Healthcare · Diagnostics & Research
Quest Diagnostics Incorporated is a Healthcare company with a market capitalization of $26.14B, a trailing P/E ratio of 25.2, and a dividend yield of 1.04%.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 21, 2026 | $2.50 | $2.37 | +5.5% |
| Q4 2025 | February 10, 2026 | $2.42 | $2.36 | +2.5% |
| Q3 2025 | October 21, 2025 | $2.60 | $2.50 | +4.0% |
| Q2 2025 | July 22, 2025 | $2.62 | $2.57 | +1.9% |
| Q1 2025 | April 22, 2025 | $2.21 | $2.15 | +2.8% |
| Q4 2024 | January 30, 2025 | $2.23 | $2.18 | +2.3% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 3,509,407 | 3.13% | 4.3 | -6.0% |
| June 30, 2026 | 3,732,507 | 3.33% | 3.8 | +9.2% |
| June 15, 2026 | 3,419,621 | 3.05% | 4.3 | -0.3% |
| May 29, 2026 | 3,430,849 | 3.06% | 4.2 | -7.7% |
| May 15, 2026 | 3,715,019 | 3.32% | 5.0 | +9.6% |
| April 30, 2026 | 3,389,572 | 3.03% | 2.6 | -4.6% |
| April 15, 2026 | 3,551,568 | 3.17% | 4.6 | -14.9% |
| March 31, 2026 | 4,174,813 | 3.73% | 4.5 | +7.8% |
Other Diagnostics & Research Stocks
Frequently Asked Questions
What is Quest Diagnostics Incorporated's market cap?
As of August 13, 2026, Quest Diagnostics Incorporated (DGX) has a market capitalization of $26.14B.
What is Quest Diagnostics Incorporated's P/E ratio?
Quest Diagnostics Incorporated trades at a trailing price-to-earnings (P/E) ratio of 25.2. Its forward P/E is 21.2.
Does Quest Diagnostics Incorporated pay a dividend?
Yes — Quest Diagnostics Incorporated pays a dividend yielding 1.04%, an annual payout of $3.32 per share.
What sector is DGX in?
Quest Diagnostics Incorporated is in the Healthcare sector, specifically the Diagnostics & Research industry.
What is Quest Diagnostics Incorporated's short interest?
As of the July 15, 2026 FINRA settlement, 3,509,407 DGX shares were sold short, or 3.13% of shares outstanding. Days to cover: 4.3. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Quest Diagnostics Incorporated's revenue?
In its latest reported fiscal year (ending December 31, 2025), Quest Diagnostics Incorporated reported revenue of $11.04B and net income of $992.00M.
Ask your own questions about DGX
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.